Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reviva Pharmaceuticals Holdings, Inc. - Common Stock (NQ:RVPH)

0.8300 +0.0300 (+3.75%)
Streaming Delayed Price Updated: 3:23 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Reviva Pharmaceuticals Holdings, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Spotify To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Top movers in Tuesday's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Which stocks are experiencing notable movement on Tuesday?
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Expert Ratings for Reviva Pharmaceuticals
Via Benzinga
Where Reviva Pharmaceuticals Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Reviva Pharmaceuticals' Schizophrenia Candidate Shows Favorable Drug-Drug Interaction Data
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a multi-receptor antipsychotic. 
Via Benzinga
Exposures Product Safety
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024
RVPH stock results show that Reviva Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024
RVPH stock results show that Reviva Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023
RVPH stock results show that Reviva Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) shares are surging after the company released topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Could This Be A Breakthrough in Mental Health? Reviva's Schizophrenia Drug Shows Promising Results In Key Trial
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) announced the topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in  
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another dive into the biggest pre-market stock movers this morning as we check out the latest news on Thursday! 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.